statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

 Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today...

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster

A Closer Look at Bristol-Myers Squibb's Options Market Dynamics

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

This Is What Whales Are Betting On Bristol-Myers Squibb

, - (NYSE:BMY) KRASG12C ( ) (cetuximab) 1/2 KRYSTAL-1 .94 11.9 (Krazati) 34% , 6.9 , 15.9 .
read more...

Bristol Myers Squibb (NYSE: BMY) today announced data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating KRAZATI (adagrasib) in combination with cetuximab for the treatment of patients...

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

In this piece, we will take a look at the five best weight loss drug stocks to buy now. If you want to take a deeper look at the latest trends in the weight loss industry, then read 10 Best Weight...

5 Best Weight Loss Drug Stocks to Buy Now

DekaBank Deutsche Girozentrale cut its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent disclosure...

DekaBank Deutsche Girozentrale Has $203.35 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT...

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Volume	1,744.00
52-Wk High	$70.94
52-Wk Low	$47.58

BMY Bristol-Myers Squibb Co.

About

Feed

News

Sentiment

Earnings

Fundamentals